ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
47 hedge funds and large institutions have $255M invested in Adaptimmune Therapeutics in 2020 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 14 increasing their positions, 10 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
9% more funds holding
Funds holding: 43 → 47 (+4)
4.61% more ownership
Funds ownership: 10.32% → 14.93% (+4.6%)
Holders
47
Holding in Top 10
–
Calls
$168K
Puts
$95K
Top Buyers
| 1 | +$34.1M | |
| 2 | +$17.5M | |
| 3 | +$10M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$5.59M |
| 5 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$3.4M |
Top Sellers
| 1 | -$2.86M | |
| 2 | -$826K | |
| 3 | -$292K | |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$226K |
| 5 |
MS
Maven Securities
St Helier,
Jersey
|
-$185K |